secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2025-02-21T23:59:59+00:00
Accession:  0001140361-25-005489
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA Biologics sets 2025 executive comp; CEO Grossman base $925k with equity awards
--------------------------------------------------------------------------------

- CEO Grossman: 2025 base $925k, 2024 cash bonus $1.02M, 252,022 RSUs, 376,744 options at $16.07 strike.
- COO Kestenberg: 2025 base $575k, 2024 bonus $293,625, 77,784 RSUs, 116,279 options.
- CFO Tade: 2025 base $500k, 2024 bonus $254,475, 62,227 RSUs, 93,023 options.
- Non-employee directors get annual equity grants of $350k (50% RSUs, 50% options) and increased committee retainers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036125005489/0001140361-25-005489-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036125005489/ef20044064_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-005489

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer